{"id":"tdf-3tc-efv","safety":{"commonSideEffects":[{"rate":"50","effect":"Dizziness and CNS effects (EFV-related)"},{"rate":"15","effect":"Nausea"},{"rate":"15","effect":"Diarrhea"},{"rate":"10","effect":"Rash"},{"rate":"10","effect":"Headache"},{"rate":"5","effect":"Renal impairment (TDF-related)"},{"rate":"5","effect":"Bone density loss (TDF-related)"}]},"_chembl":null,"_fixedAt":"2026-03-30T12:26:03.205914","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TDF (tenofovir disoproxil fumarate) and 3TC (lamivudine) are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, while EFV (efavirenz) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that also targets the same enzyme through a different mechanism. Together, these three agents provide potent suppression of HIV-1 replication by preventing the conversion of viral RNA to DNA.","oneSentence":"This is a fixed-dose combination antiretroviral regimen that inhibits HIV reverse transcriptase and integrase to suppress viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:28.702Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"}]},"_fixedFields":["pubmed(66)"],"trialDetails":[{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02284035","phase":"PHASE3","title":"Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2015-09-27","conditions":"AIDS","enrollment":75},{"nctId":"NCT02652260","phase":"PHASE2","title":"Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-03-04","conditions":"HIV-1, Central Nervous System","enrollment":86},{"nctId":"NCT06619288","phase":"","title":"Good-first: B/F/TAF As First-line ART","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-07-01","conditions":"HIV Infection","enrollment":630},{"nctId":"NCT01837277","phase":"PHASE2, PHASE3","title":"Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients","status":"COMPLETED","sponsor":"Fundação Bahiana de Infectologia","startDate":"2017-12-15","conditions":"Severely Immunocompromised HIV Patients","enrollment":186},{"nctId":"NCT04022967","phase":"PHASE3","title":"ANRS 12372 MODERATO Study","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-09-21","conditions":"HIV-1-infection","enrollment":480},{"nctId":"NCT00350272","phase":"PHASE2","title":"Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2006-05","conditions":"HIV Infections","enrollment":76},{"nctId":"NCT04433780","phase":"PHASE3","title":"DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2021-01-04","conditions":"HIV-1-infection","enrollment":133},{"nctId":"NCT03916328","phase":"PHASE4","title":"BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study","status":"UNKNOWN","sponsor":"MU-JHU CARE","startDate":"2019-12-03","conditions":"Bone Loss","enrollment":330},{"nctId":"NCT04296695","phase":"PHASE4","title":"Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-07-14","conditions":"HIV-1-infection","enrollment":250},{"nctId":"NCT04424264","phase":"PHASE1","title":"The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2019-12-05","conditions":"HIV-1-infection, Tuberculosis","enrollment":18},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT02249962","phase":"","title":"Option B+: Study on Safety, Viral Suppression, and Survival on Second Line ART","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2015-05","conditions":"HIV, Infant Exposure to Efavirenz","enrollment":12011},{"nctId":"NCT03284645","phase":"","title":"Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids","status":"COMPLETED","sponsor":"Obafemi Awolowo University","startDate":"2017-12-22","conditions":"Human Immunodeficiency Virus Infection","enrollment":194},{"nctId":"NCT03076359","phase":"NA","title":"Traditional Healers as Adherence Partners for Persons Living With HIV in Rural Mozambique","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2015-06-10","conditions":"HIV/AIDS","enrollment":320},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT01160120","phase":"PHASE2","title":"Therapeutic Drug Monitoring (TDM) in Generic Tenofovir/Lamivudine/Efavirenz","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2010-06","conditions":"HIV","enrollment":100},{"nctId":"NCT03405194","phase":"NA","title":"Same-Day Treatment With Genvoya vs. EFV/TDF/3TC","status":"WITHDRAWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2018-05-01","conditions":"HIV/AIDS","enrollment":""},{"nctId":"NCT04303598","phase":"PHASE3","title":"Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive Patients","status":"UNKNOWN","sponsor":"Henan Genuine Biotech Co., Ltd.","startDate":"2020-04-01","conditions":"HIV-infection/Aids","enrollment":720},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT03595709","phase":"PHASE3","title":"Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan","status":"COMPLETED","sponsor":"Yu-Jay Corp.","startDate":"2018-12-06","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT04109183","phase":"PHASE2","title":"A Drug Safety and Dose-exploratory Clinical Study of Azvudine Tablets in Patients Who Have Not Received Anti-HIV Treatment","status":"COMPLETED","sponsor":"Henan Genuine Biotech Co., Ltd.","startDate":"2017-10-10","conditions":"AIDS","enrollment":172},{"nctId":"NCT02750059","phase":"PHASE2","title":"Using Telmisartan With ART During Acute HIV Infection to Reduce the CNS Reservoirs of HIV and Lymph Node Fibrosis","status":"COMPLETED","sponsor":"SEARCH Research Foundation","startDate":"2015-01","conditions":"Acute HIV Infection, HIV CNS Involvement","enrollment":21},{"nctId":"NCT02273765","phase":"PHASE3","title":"Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2015-09-11","conditions":"HIV-1 Infection, Tuberculosis","enrollment":460},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00118898","phase":"PHASE3","title":"Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-09","conditions":"HIV Infections","enrollment":1864},{"nctId":"NCT00084136","phase":"PHASE4","title":"Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-05","conditions":"HIV Infections","enrollment":1571},{"nctId":"NCT00427297","phase":"PHASE3","title":"Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya","status":"TERMINATED","sponsor":"University of Washington","startDate":"2007-09","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT01891799","phase":"","title":"Swaziland Safe Generations","status":"COMPLETED","sponsor":"Columbia University","startDate":"2013-08","conditions":"HIV/AIDS","enrollment":2518},{"nctId":"NCT02499874","phase":"PHASE1","title":"SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-08","conditions":"HIV","enrollment":26},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT02832778","phase":"PHASE1","title":"Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid","status":"UNKNOWN","sponsor":"St Stephens Aids Trust","startDate":"2016-11-21","conditions":"HIV","enrollment":35},{"nctId":"NCT02632474","phase":"PHASE4","title":"ART Drug Dosage Adjustment in HIV-infected Population","status":"COMPLETED","sponsor":"Shanghai Public Health Clinical Center","startDate":"2015-04","conditions":"HIV Infections","enrollment":10},{"nctId":"NCT02827643","phase":"NA","title":"Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2016-06","conditions":"Bone Density","enrollment":48},{"nctId":"NCT01489046","phase":"PHASE2","title":"Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2011-02","conditions":"HIV-1 Infection","enrollment":297},{"nctId":"NCT01340950","phase":"PHASE4","title":"Clinical Trial of Brain-Penetrating HIV Drugs to Prevent Cognitive Impairment in China","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2010-07","conditions":"HIV Infections, Central Nervous System Diseases, Dementia","enrollment":250},{"nctId":"NCT00100048","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-01","conditions":"HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":206},{"nctId":"NCT02421289","phase":"PHASE1","title":"Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2013-04","conditions":"Cytochrome P-450 CYP2B6, Efavirenz, HIV","enrollment":190},{"nctId":"NCT00192595","phase":"PHASE4","title":"Tenofovir in HIV/HBV Coinfection","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2004-01","conditions":"HIV Infection, Hepatitis B Coinfection","enrollment":36},{"nctId":"NCT01583439","phase":"NA","title":"The Mochudi Prevention Project ART Protocol","status":"TERMINATED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2012-09","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT00978237","phase":"PHASE4","title":"Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2009-10","conditions":"HIV Infections, Lipoatrophy","enrollment":20},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT01751555","phase":"PHASE4","title":"Efficacy and Safety of TDF+3TC+EFV in Adults With HIV/HBV Coinfection","status":"COMPLETED","sponsor":"National Center for AIDS/STD Control and Prevention, China CDC","startDate":"2011-02","conditions":"Hiv","enrollment":100},{"nctId":"NCT00158821","phase":"PHASE3","title":"Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2000-03","conditions":"HIV Infections","enrollment":180},{"nctId":"NCT01844297","phase":"NA","title":"Efficacy and Safety of Tenofovir Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy","status":"UNKNOWN","sponsor":"Peking Union Medical College","startDate":"2013-05","conditions":"AIDS/HIV PROBLEM","enrollment":500},{"nctId":"NCT01159743","phase":"","title":"A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-07","conditions":"HIV Infection","enrollment":346},{"nctId":"NCT00666055","phase":"","title":"Sex, Aging and Antiretroviral Pharmacokinetics","status":"COMPLETED","sponsor":"Kristine Patterson, MD","startDate":"2008-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00192660","phase":"PHASE4","title":"HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2003-02","conditions":"HIV-Associated Lipodystrophy Syndrome, Cardiovascular Disease","enrollment":80},{"nctId":"NCT00936195","phase":"PHASE3","title":"Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial","status":"WITHDRAWN","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2010-01","conditions":"HIV Infection, Pregnancy, Breastfeeding","enrollment":""},{"nctId":"NCT00549198","phase":"PHASE4","title":"KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06","conditions":"Infection, Human Immunodeficiency Virus I, HIV Infection","enrollment":392},{"nctId":"NCT01318096","phase":"NA","title":"Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients","status":"UNKNOWN","sponsor":"Yunnan AIDS Care Center","startDate":"2011-03","conditions":"HBV Coinfection, HIV Infections","enrollment":60},{"nctId":"NCT00112047","phase":"PHASE3","title":"Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-07","conditions":"HIV Infections","enrollment":517},{"nctId":"NCT00615810","phase":"PHASE4","title":"ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-03","conditions":"HIV Infections","enrollment":159},{"nctId":"NCT00643968","phase":"PHASE4","title":"Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-03","conditions":"HIV Infections","enrollment":140},{"nctId":"NCT00433056","phase":"PHASE3","title":"Long Term Treatment Interruptions","status":"COMPLETED","sponsor":"A.O. Ospedale Papa Giovanni XXIII","startDate":"2004-01","conditions":"HIV Infections, AIDS","enrollment":320},{"nctId":"NCT00038220","phase":"PHASE2","title":"Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients","status":"COMPLETED","sponsor":"Abbott","startDate":"2000-07","conditions":"HIV Infections","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":66,"recentPublications":[{"date":"2026 Feb 11","pmid":"41673590","title":"Clinical and biological risk factors influencing infant HIV status: a case study of Kisenyi Health Center IV, Kampala, Uganda.","journal":"BMC infectious diseases"},{"date":"2026 Mar 4","pmid":"41631851","title":"Effectiveness and safety of ainuovirine plus lamivudine and tenofovir DF in virologically suppressed people living with HIV-1: the 48-week results of a multicenter, real-world study.","journal":"Antimicrobial agents and chemotherapy"},{"date":"2026 Feb","pmid":"41627869","title":"Geographical and temporal trends of HIV-1 subtypes and drug resistance in China: a nationwide study over two decades (2003-2024).","journal":"The Journal of general virology"},{"date":"2025","pmid":"41623630","title":"HIV-1 drug resistance and genetic clustering among ART-treated individuals with virologic failure in Aksu, China.","journal":"Frontiers in microbiology"},{"date":"2025","pmid":"41183094","title":"Incidence of antiretroviral therapy regimen modification and associated factors among People Living with HIV in Beijing, China.","journal":"PLOS global public health"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tenofovir /Ravmidine /Efavirenz"],"phase":"marketed","status":"active","brandName":"TDF/3TC/EFV","genericName":"TDF/3TC/EFV","companyName":"Peking Union Medical College Hospital","companyId":"peking-union-medical-college-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a fixed-dose combination antiretroviral regimen that inhibits HIV reverse transcriptase and integrase to suppress viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}